Free Newsletter
Vaccine expert's autism defense triggers reaction
When vaccine expert Paul Offit released his new book defending vaccines against the attacks of critics claiming a link to autism, he had a new security system installed at his house. Rates of autism and other related neurological conditions have increased to one in 150 children, and a number of parents believe--despite a huge amount of data to the contrary--that vaccines are responsible. And when Offit continues to counter their arguments, the discussion can turn heated.
Offit made a significant amount of money from Rotateq, a rotavirus vaccine he helped to develop along with two other researchers. Now he devotes much of his time to trying to quell public fears about vaccines--at some risk of retaliation. His new book is Autism's False Prophets: Bad Science, Risky Medicine, and the Search for a Cure.
"We put a new security system on our house as a way of celebrating the launch of this book," Offit told the Philadelphia Inquirer. "Which I think most authors don't do. Maybe Salman Rushdie."
- read the report from the Philadelphia Inquirer
ALSO: An Australian couple spent four weeks on the run rather than provide a hepatitis B vaccine to their newborn. Report
Related Articles:
MIT scientists reverse autism, retardation in mice
Pediatricians get tough with vaccine doubters
Many infants don't get vaccinations on time
Paid Research Reports
- The Specialty Pharma Market Outlook: Key players, new company growth models and emerging opportunities
- Investigating Clinical Trial Costs: Comparative analysis of trial cost components in key geographies
- Clinical Trial Recruitment Strategies: Optimizing patient recruitment and retention in late stage clinical trials
- Pipeline Insight: Therapeutic Cancer Vaccines - Prospect of first approval set to reinvigorate interest from major companies
- Stakeholder Opinions: Vaccines in Emerging Markets (Asia) - Opportunities in China, India, South Korea and Taiwan
- Big Pharma Performance Before, During and Beyond the Global Recession




